Rising Biosciences(RBII)
$0.000.00 (0.00%)
RBII
Rising Biosciences financials statements
$0.00
At close:0.00 (0.00%)
Rising Biosciences (RBII) Ratios
21 Followers
Rising Biosciences Ratios
RBII's free cash flow for Q? was ―. For the fiscal year, RBII's free cash flow was increased by ― and operating cash flow was ―. See a summary of the company’s cash flow.
| Ratios | Dec 20 | Dec 19 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 0.12 | 0.00 |
| Quick Ratio | 0.10 | 0.00 |
| Cash Ratio | 0.03 | 0.00 |
| Solvency Ratio | 0.05 | -0.14 |
| Operating Cash Flow Ratio | -0.04 | -0.04 |
| Short-Term Operating Cash Flow Coverage | -0.07 | -0.06 |
| Net Current Asset Value | $ -1.52M | $ -1.56M |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 1.65 | 2.37 |
| Debt-to-Equity Ratio | -0.97 | -0.82 |
| Debt-to-Capital Ratio | -31.66 | -4.48 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.59 | -0.35 |
| Debt Service Coverage Ratio | 0.14 | -0.14 |
| Interest Coverage Ratio | 4.09 | -2.43 |
| Debt to Market Cap | 0.83 | 1.87 |
| Interest Debt Per Share | 0.00 | 0.00 |
| Net Debt to EBITDA | 6.60 | -6.49 |
| Profitability Margins | ||
| Gross Profit Margin | 57.32% | -42.10% |
| EBIT Margin | 15.23% | -109.48% |
| EBITDA Margin | 19.52% | -89.01% |
| Operating Profit Margin | 36.33% | -109.48% |
| Pretax Profit Margin | 6.36% | -154.66% |
| Net Profit Margin | 6.36% | -154.66% |
| Continuous Operations Profit Margin | 6.36% | -154.66% |
| Net Income Per EBT | 100.00% | 100.00% |
| EBT Per EBIT | 17.51% | 141.27% |
| Return on Assets (ROA) | 7.77% | -63.30% |
| Return on Equity (ROE) | -4.57% | 21.88% |
| Return on Capital Employed (ROCE) | -26.08% | 15.49% |
| Return on Invested Capital (ROIC) | -851.75% | 84.96% |
| Return on Tangible Assets | 7.77% | -63.30% |
| Earnings Yield | 3.91% | -50.02% |
| Efficiency Ratios | ||
| Receivables Turnover | 6.46 | 0.00 |
| Payables Turnover | 6.87 | 4.78 |
| Inventory Turnover | 8.45 | 0.00 |
| Fixed Asset Turnover | 2.85 | 0.54 |
| Asset Turnover | 1.22 | 0.41 |
| Working Capital Turnover Ratio | -0.51 | 0.00 |
| Cash Conversion Cycle | 46.54 | -76.39 |
| Days of Sales Outstanding | 56.48 | 0.00 |
| Days of Inventory Outstanding | 43.21 | 0.00 |
| Days of Payables Outstanding | 53.15 | 76.39 |
| Operating Cycle | 99.69 | 0.00 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -23447.67 | -0.73 |
| Capital Expenditure Coverage Ratio | -23447.67 | -0.73 |
| Operating Cash Flow Coverage Ratio | -0.07 | -0.06 |
| Operating Cash Flow to Sales Ratio | -0.09 | -0.36 |
| Free Cash Flow Yield | -5.53% | -27.80% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | 25.56 | -2.00 |
| Price-to-Sales (P/S) Ratio | 1.63 | 3.09 |
| Price-to-Book (P/B) Ratio | -1.17 | -0.44 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -18.08 | -3.60 |
| Price-to-Operating Cash Flow Ratio | -18.08 | -8.52 |
| Price-to-Earnings Growth (PEG) Ratio | -0.26 | 0.00 |
| Enterprise Value Multiple | 14.93 | -9.96 |
| Enterprise Value | 2.28M | 1.45M |
| EV to EBITDA | 14.93 | -9.96 |
| EV to Sales | 2.91 | 8.87 |
| EV to Free Cash Flow | -32.41 | -10.31 |
| EV to Operating Cash Flow | -32.41 | -24.43 |
| Tangible Book Value Per Share | -0.00 | -0.00 |
| Shareholders’ Equity Per Share | -0.00 | -0.00 |
| Tax and Other Ratios | ||
| Effective Tax Rate | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 |
| Net Income Per Share | 0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 |
| Interest Burden | 0.42 | 1.41 |
| Research & Development to Revenue | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 |
| Income Quality | -1.41 | 0.23 |
Currency in USD
